I am overexposed to this stock, but let's be realistic. If the Parkinson's disease trial has unimpressive results, it will be a few months before there is another catalyst for Anavex, namely topline results in Rett syndrome by the end of the year, if all goes according to plan. I wish they had started trials with Anavex 3-71 a couple of years ago.
Endless positive, uncritical posts will not change the way the scientific and business worlds view this company. Rather, it will take more results like the preliminary findings in Rett syndrome to start to make a difference.
Realistically, this stock could indeed fall back to 2.50.